Company intelligence / Profile preview

Emerald Medical

San Diego, California, United Statesemerald-medical.com ↗

Ownership: Private
Development stage: Preclinical

Overview

EHP‑101 has entered Phase 2 clinical development for systemic sclerosis and multiple sclerosis. EHP‑102 is in preclinical development targeting Parkinson’s disease and Huntington’s disease. Both candidates have received Orphan Drug Designation in the US/EU for their respective indications.

Therapeutic areas: RheumatologyNeurology
Modalities: Small molecule (novel chemical entities derived from cannabinoids)Synthetic cannabinoid derivatives
Industry: Biotech

Drug pipeline

2 assets

SCS

Pre-clinical

Indications: Hydrocephalus, Normal Pressure Hydrocephalus

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Emerald Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Emerald Medical.

Explore the full profile